147 related articles for article (PubMed ID: 20939473)
1. [Effectiveness of low molecular weight heparin for prevention of deep vein thrombosis after total hip arthroplasty].
Yang Z; Liu X; Dai S; Liu K; Zhang Y; Sun J; Yin X
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2010 Sep; 24(9):1058-61. PubMed ID: 20939473
[TBL] [Abstract][Full Text] [Related]
2. [Low-molecular-weight heparin for preventing deep-vein thrombosis after total joint arthroplasty].
Yang G; Lu H; Gao J; Kou B; Yuan Y; Xu B
Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):25-7. PubMed ID: 11831980
[TBL] [Abstract][Full Text] [Related]
3. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 3,000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German Thrombosis Study Group.
Adolf J; Fritsche HM; Haas S; Hennig FF; Horbach T; Kastl S; Koppenhagen K; Michaelis HC; Rhamanzadeh R; Summa W; Wagner W; Weber U; Wolf H
Int Angiol; 1999 Jun; 18(2):122-6. PubMed ID: 10424367
[TBL] [Abstract][Full Text] [Related]
5. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
Whang PG; Lieberman JR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
[TBL] [Abstract][Full Text] [Related]
6. [A combination of arteriovenous impulse system and low-molecular-weight heparins calcium for prophylaxis of deep venous thrombosis following total knee arthroplasty].
Cao J; Wang J; Zhang H; Wang L
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2010 May; 24(5):538-40. PubMed ID: 20540254
[TBL] [Abstract][Full Text] [Related]
7. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
8. [Prophylaxis for deep vein thrombosis with low molecular weight heparin following hip and knee surgery].
Li XL; Lu WJ; Yu NS
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2001 Jan; 15(1):39-41. PubMed ID: 12563929
[TBL] [Abstract][Full Text] [Related]
9. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
10. [Influence of body mass index and age on deep vein thrombosis after total hip and knee arthroplasty].
Guan Z; Chen Y; Song Y
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Jun; 20(6):611-5. PubMed ID: 16827383
[TBL] [Abstract][Full Text] [Related]
11. DVT prevention: mobile compression device vs low-molecular-weight heparin.
Colwell CW
Orthopedics; 2010 May; 33(5):317-8. PubMed ID: 20507033
[No Abstract] [Full Text] [Related]
12. Deep vein thrombosis prophylaxis: a comprehensive approach for total hip and total knee arthroplasty patient populations.
Miric A; Lombardi P; Sculco TP
Am J Orthop (Belle Mead NJ); 2000 Apr; 29(4):269-74. PubMed ID: 10784014
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparin for deep vein thrombosis in glioma patients.
Schmidt F; Faul C; Dichgans J; Weller M
J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
[TBL] [Abstract][Full Text] [Related]
14. Venous thrombosis prophylaxis with low-molecular-weight heparin in hip and knee arthroplasty.
Colwell CW
Instr Course Lect; 2002; 51():487-9. PubMed ID: 12064138
[No Abstract] [Full Text] [Related]
15. Clinical implications of thromboprophylaxis in the management of total hip and knee arthroplasty.
Skinner HB; Schulz MM
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):20-30. PubMed ID: 12349892
[TBL] [Abstract][Full Text] [Related]
16. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
Marchetti M; Liberato NL; Ruperto N; Barosi G
Haematologica; 1999 Aug; 84(8):730-7. PubMed ID: 10458700
[TBL] [Abstract][Full Text] [Related]
17. [Clinical risk factors for deep vein thrombosis after total hip and knee arthroplasty].
Guan ZP; Lü HS; Chen YZ; Song YN; Qin XL; Jiang J
Zhonghua Wai Ke Za Zhi; 2005 Oct; 43(20):1317-20. PubMed ID: 16271243
[TBL] [Abstract][Full Text] [Related]
18. Relative risk factors for requirement of blood transfusion after total hip arthroplasty.
Walsh M; Preston C; Bong M; Patel V; Di Cesare PE
J Arthroplasty; 2007 Dec; 22(8):1162-7. PubMed ID: 18078885
[TBL] [Abstract][Full Text] [Related]
19. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
[TBL] [Abstract][Full Text] [Related]
20. [Effect of bone cement application on the incidence of deep vein thrombosis in major joint arthroplasties].
Aslan A; Ağar E; Aydoğan NH; Atay T; Baydar ML; Kırdemir V; Ozden A
Eklem Hastalik Cerrahisi; 2011 Dec; 22(3):149-54. PubMed ID: 22085350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
